UCB ups stake in oncology partner

UCB has upped its investment in Wilex, acquiring an additional 6.65 percent of the oncology company's shares to bring its total holdings to about 18 percent. Wilex acquired five oncology projects from UCB in early 2009, and one of those programs--MEK inhibitor WX554--is now in Phase I development. UCB announcement